Frontier of Renal Outcome Modifications in Japan(FROM-J)cohort study
Not Applicable
- Conditions
- chronic kidney disease
- Registration Number
- JPRN-UMIN000008378
- Lead Sponsor
- niversity of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who is dropout from FROM-J study 2. Patients who revoke the informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Discontinuation rate of general practice physicians consultation 2. Good communication rate between general practice physicians and nephrologists 3. Progression of CKD stages
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways (e.g., TGF-β, Wnt/β-catenin) are associated with CKD progression in the FROM-J2 observational cohort?
How do biomarkers like APOL1 or UMOD predict CKD outcomes in the FROM-J2 study compared to other Japanese cohorts?
What are the key risk factors for adverse events (e.g., cardiovascular, anemia) identified in the FROM-J2 CKD cohort?
How does FROM-J2 data on SGLT2 inhibitors and RAS inhibitors inform CKD management in Japan?
What genetic or proteomic markers correlate with CKD progression in the FROM-J2 study versus international trials?